HIV

Lancet. 2018 Aug 25;392(10148):685-697. doi: 10.1016/S0140-6736(18)31311-4. Epub 2018 Jul 23.

Abstract

The benefits of combination antiretroviral therapy (cART) for HIV replication and transmission control have led to its universal recommendation. Many people living with HIV are, however, still undiagnosed or diagnosed late, especially in sub-Saharan Africa, where the HIV disease burden is highest. Further expansion in HIV treatment options, incorporating women-centred approaches, is essential to make individualised care a reality. With a longer life expectancy than before, people living with HIV are at an increased risk of developing non-AIDS comorbidities, such as cardiovascular diseases and cancers. Antiretroviral strategies are evolving towards a decrease in drug burden, and some two-drug combinations have proven efficacy for maintenance therapy. Investigational immune checkpoint inhibitors and broadly neutralising antibodies with effector functions have energised the HIV cure research field as the search for an effective vaccine continues. In this Seminar, we review advances and challenges relating to the goal of an AIDS-free world.

Publication types

  • Review

MeSH terms

  • Africa South of the Sahara / epidemiology
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / therapeutic use*
  • Anti-Retroviral Agents / therapeutic use
  • Comorbidity / trends
  • Cost of Illness
  • Drug Therapy, Combination / methods
  • Female
  • Global Health / education
  • Global Health / statistics & numerical data
  • HIV / drug effects*
  • HIV / genetics
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology*
  • HIV Infections / prevention & control
  • HIV Infections / transmission
  • Humans
  • Infectious Disease Transmission, Vertical / prevention & control
  • Life Expectancy / trends
  • Male
  • Sexually Transmitted Diseases / prevention & control
  • Sexually Transmitted Diseases / virology
  • Survival Analysis

Substances

  • Anti-HIV Agents
  • Anti-Retroviral Agents